stockrowAxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.
- Revenue
- +26.2%
- EPS
- +178.3%
- Free cash flow
- +995.0%
- Total debt
- −73.1%
Quarter to September 2026, against a year earlier
Follow AXGN
Alert me
AxoGen, Inc. (AXGN) Shares outstanding
AxoGen, Inc.'s shares outstanding at the end of fiscal 2025 was $46.1M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $61.5M. Over the past ten years it has ranged from $26.1M (fiscal 2015) to $46.1M (fiscal 2025) — the current reading is the highest in ten years. AxoGen, Inc. ranks 46th of 147 Medical Devices companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $46.1M | 4.05% |
| FY2024 | $44.3M | 3.22% |
| FY2023 | $42.9M | 1.89% |
| FY2022 | $42.1M | 2.11% |
| FY2021 | $41.2M | 3.12% |
| FY2020 | $40.0M | 1.87% |
| FY2019 | $39.2M | 5.68% |
| FY2018 | $37.1M | 11.42% |
| FY2017 | $33.3M | 8.54% |
| FY2016 | $30.7M | 17.74% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $61.5M | 15.35% |
| Jun 2026 | $53.3M | 3.39% |
| Mar 2026 | $51.6M | 12.03% |
| Dec 2025 | $46.1M | (6.19%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| NEOG Neogen Corporation compare | $218.1M |
| ALMR Alamar Biosciences, Inc. compare | $69.1M |
| AXGN AxoGen, Inc. | $61.5M |
| TMDX TransMedics Group, Inc. compare | $40.8M |
| ITGR Integer Holdings Corporation compare | $34.6M |
| IRTC iRhythm Holdings, Inc. compare | $33.1M |
| ESTA Establishment Labs Holdings Inc. compare | $30.1M |
| INSP Inspire Medical Systems, Inc. compare | $28.9M |
| UFPT UFP Technologies, Inc. compare | $7.8M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on AXGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement